E. Odenwald

发表

Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia.

K. Welte, A. Reiter, W. Muller, 1990, Blood.

BFM trials for childhood non-Hodgkin’s lymphomas

G. Henze, H. Riehm, S. Müller-Weihrich, 1985 .

Myelodysplastic Syndromes in Childhood: Report of 21 Patients from Italy and West Germany

G. Masera, J. Ritter, U. Creutzig, 1987, The American journal of pediatric hematology/oncology.

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000

J. Harbott, M. Schrappe, G. Henze, 2010, Leukemia.

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995

J. Harbott, M. Schrappe, G. Henze, 2000, Leukemia.

Prediction of Outcome by Early Response in Childhood Acute Lymphoblastic Leukemia

M. Schrappe, A. Attarbaschi, A. Möricke, 2013, Klinische Pädiatrie.

Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia

B. Meissner, M. Schrappe, A. Attarbaschi, 2012, Haematologica.

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

J. Harbott, M. Schrappe, G. Henze, 2000, Leukemia.

Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86.

E. Thiel, J. Harbott, C. Bartram, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (ALL) in children: experiences of the ALL-BFM 83 and 86 studies].

B. Komischke, C. Sperling, J. Ritter, 1990, Klinische Padiatrie.

TREATMENT OF CHILDHOOD ALL 3123 an increased leukemic cell

W. Hiddemann, M. Schrappe, G. Henze, 2002 .

Clinicopathological features and prognostic implications of immunophenotypic subgroups in childhood ALL: experience of the BFM-ALL Study 83.

B. Komischke, H. Riehm, W. Ludwig, 1989, Haematology and blood transfusion.

Prognostic Impact of Age in Children and Adolescents with Acute Lymphoblastic Leukemia: Data from the Trials ALL-BFM 86, 90, and 95

J. Harbott, M. Schrappe, W. Ludwig, 2005, Klinische Padiatrie.

Use of monoclonal antibodies as a diagnostic tool in human leukemia

F. Herrmann, B. Komischke, W. Ludwig, 1983, Blut.

[NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 1: Classification and allocation to strategic therapy groups. BIF study group].

M. Tiemann, M. Schrappe, R. Parwaresch, 1994, Klinische Padiatrie.

Electronic platelet counting with capillary blood samples—Experiences in a paediatric clinic

H. Gadner, H. Riehm, W. Hitzig, 1978, European Journal of Pediatrics.